This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


 Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Oct. 19, 2013




Acute hepatitis and liver failure following the use of a dietary supplement Intended for weight loss or muscle building
On Sept. 9, the Hawaii Department of Health (HDOH) was notified of seven patients with severe acute hepatitis and fulminant liver failure of unknown etiology. Patients were previously healthy and sought medical care during May-September 2013. Clinicians reported that the seven patients had all used OxyELITE Pro, a dietary supplement marketed for weight loss and muscle gain, before illness onset. The HDOH, with the CDC and the Food and Drug Administration (FDA), initiated a public health investigation including patient interviews, medical chart reviews and collection of supplement samples for analysis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article



Abstract deadline Oct. 31 for AST's Cutting Edge of Transplantation 2014
AST presents the Cutting Edge of Transplantation Feb. 13-15, 2014, at the Sheraton Wild Horse Pass in Chandler, AZ. Submit your basic, clinical or translational abstract related to the CEOT 2014 meeting topic: "Optimizing Long-Term Transplant Survival: Therapeutics, Targets, Technologies." Abstracts will be presented in mini-oral and/or poster format. All abstracts presented at CEOT will receive focused attention and constructive feedback from attendees and faculty. View the preliminary program now to see what will be covered, and check back often as expert faculty are being announced soon. Registration opens in October—don't miss your chance to secure a place at the limited attendance meeting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE

AST Institutional Support Program
  • Are you interested in receiving recognition and increased exposure for your transplant center?
  • Does your center support the future of transplantation and value the educational, networking, and research opportunities that the American Society of Transplantation (AST) provides to its members?
  • Does your center support AST's lobbying of the U.S. Congress and Federal Agencies to secure a more transplant provider friendly environment for patients and physicians?

    If the answer to these questions is YES, consider having your center participate in AST's 2014 Institutional Support Program. With a charitable contribution of $3,000 to support AST’s research, professional education, and advocacy programs, your center will receive valuable benefits. All donations are tax-deductible. For more information and to make a contribution, click here.

  • Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

    Live Webinars Oct. 22, Nov. 19, Dec. 17: CMV Consensus and ID Guidelines, IPITA Conference Summary, Improving Adherence
    The Timely Topics in Transplantation webinar series is free to AST members and only $25 per webinar for non-members. Click here to register, members just use your AST username and password during registration to waive the fee!
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


    Widely pescribed Statin could help organ-transplant patients
    Scientific American
    A trawl of existing data has identified drugs that seem to stall organ rejection in patients who have undergone transplants. By crunching through large, publicly available data sets, researchers pinpointed a suite of genes involved in organ rejection. They were then able to identify drugs that affect the activity of these genes—with candidates including a widely prescribed statin, a class of drug used to lower blood-cholesterol levels. A subsequent analysis of thousands of medical records indicated that statins do in fact help transplant patients.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

    World first: Lungs awaiting transplant preserved 11 hours outside body
    Medical Xpress
    The multidisciplinary transplant team at University Hospitals Leuven successfully preserved a set of donor lungs for over eleven hours with the help of a machine, the longest period ever reported. The lengthy preservation time was necessary because the patient needed a liver transplant immediately prior to the lung transplant. The patient has since left the hospital and is in good health.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

    Featured Advertisers


    Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities to help improve the transplant experience. Together. Please visit
    University of Vermont Transplant Nephrologist

    The University of Vermont/Fletcher Allen Health Care is seeking applications for a senior faculty member to join the Division of Nephrology. The candidate should be UNOS certified in kidney and pancreas transplants, experienced in educating nephrology fellows, growing transplant programs, and providing administrative leadership. Apply Here
    The FlowSight offers high performance in a small package. Its innovative design increases signal and minimizes noise to provide unmatched fluorescence sensitivity. Twelve standard detection channels simultaneously produce brightfield, darkfield and up to ten channels of fluorescence imagery of every cell. More info

    Analyses: Outcomes in ethnic minority renal transplant recipients receiving everolimus versus mycophenolate
    Transplantation (login required)
    Everolimus (EVR) has demonstrated good efficacy after renal transplantation. Racial disparities in clinical outcomes after de novo renal transplantation are well documented; whether the efficacy of EVR varies based on recipient ethnicity is unknown. We conducted a comparative risk assessment of EVR by ethnicity.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

    Antiviral treatment for hepatitis B virus recurrence following liver transplantation
    Clinical Transplantation (login required)
    The purpose of this study was to identify the factors associated with the recurrence of hepatitis B virus (HBV) following liver transplantation (LT) for HBV-related disease and to recognize the outcome of treatment for HBV recurrence with oral nucleos(t)ide analogues. Six hundred and sixty-seven LTs were performed for HBsAg-positive adult patients in our institute from 1996 to 2010.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

    Missed last week's issue? See which articles your colleagues read most.

        Trial: Transplanting the highly sensitized patient (NCBI)
    Gender issues in solid organ donation and transplantation (NCBI)
    Pretransplant sensitization against angiotensin II type 1 receptor is a riskfactor for acute rejection and graft loss (American Journal of Transplantation)
    Survey: Screening recipients of increased-risk donor organs (Transplant Infectious Disease)
    Low incidence of pneumocystis jirovecii pneumonia in an unprophylaxed liver transplant cohort (Transplant Infectious Disease)

    Don't be left behind. Click here to see what else you missed.

    Young transplant patients 'at higher risk of kidney disease'
    MedicalNews Today
    A new national study from U.S. researchers suggests that children who undergo solid organ transplants are at higher risk of developing advanced kidney disease. Researchers from the Children's Hospital of Philadelphia and the University of Pennsylvania say their findings emphasize the importance of continued kidney screening in pediatric transplant patients.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

    Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients
    Pediatric Transplantation (login required)
    Sirolimus is used in heart transplant patients with CAV and CNI-induced nephropathy. However, little is known regarding the tolerability, rejection rate and effect on renal function when used empirically in children. This article describes the authors' experience with the empiric use of a sirolimus-based immunosuppressive regimen in pediatric heart transplantation recipients.
    Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

    AST eNews

    Colby Horton, Vice President of Publishing, 469.420.2601
    Download media kit

    Courtney Hodges, Content Editor, 972.402.2604   
    Contribute news

    This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

    Recent issues
    Oct. 11, 2013
    Oct. 4, 2013
    Sept. 27, 2013
    Sept. 20, 2013

    7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063